AstraZeneca Says Its Coronavirus Vaccine Triggers Immune Response Among Older and Younger Adults

AstraZeneca this morning announced that its potential COVID-19 vaccine has produced a similar immune response in both older and younger adults, reports CNBC News . AstraZeneca, which is developing its potential vaccine with the University of Oxford, said adverse responses to the vaccine among senior men and women were also found to be lower. The World Health Organization has said that older adults, in addition to people of all ages with pre-existing medical conditions, have been prone to developing serious illness on contracting the coronavirus more so than others. This latest announcement is likely to boost hopes of a vaccine being developed prior to the end of 2020. "It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher," an AstraZeneca spokesman commented. "The results further build the body of evidence for the safety and immunogenicity of AZD1222 the technical name of the AstraZeneca-Oxford vaccine."